Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | SOD1 | P00441 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9561885 | 0.91 | MRGPRX4 (0.53) | MRGPRX4MAOBNR4A2NPC1RAB9A | |
| SCHEMBL4452776 | 0.85 | HIF1A (0.61) | MRGPRX4NR4A2NPC1RAB9AFOLH1 | |
| SCHEMBL9128160 | 0.85 | HIF1A (0.52) | MRGPRX4MAOBNPC1RAB9AALDH1A1 | |
| SCHEMBL1368181 | 0.84 | TP53 (0.63) | MRGPRX4NR4A2NPC1RAB9AFOLH1 | |
| SCHEMBL1756444 | 0.84 | MRGPRX4 (0.63) | MRGPRX4NR4A2NPC1RAB9AFOLH1 | |
| SCHEMBL4215754 | 0.84 | NR4A2 (0.59) | MRGPRX4NR4A2NPC1RAB9AFOLH1 | |
| SCHEMBL3142013 | 0.83 | MRGPRX4 (0.56) | MRGPRX4NR4A2FOLH1ALDH1A1TP53 | |
| SCHEMBL11572828 | 0.82 | MRGPRX4 (0.64) | MRGPRX4NR4A2NPC1RAB9AFOLH1 | |
| SCHEMBL10920832 | 0.82 | PTGES (0.51) | MRGPRX4MAOBNR4A2NPC1RAB9A | |
| SCHEMBL9127513 | 0.82 | MRGPRX4 (0.51) | MRGPRX4MAOBNR4A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2011-10-06 | — | — | US | disclosed |
| EP-0409406-B1 | ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-08 | — | — | EP | disclosed |
| EP-0487502-A2 | Pharmaceutically active aryl-substituted amine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-27 | — | — | EP | disclosed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | disclosed |
| US-4923892-A | DOXEPIN DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0214779-B1 | TRICYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0351887-A1 | Tricyclic aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-24 | — | — | EP | disclosed |
| US-4871865-A | ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0316022-A2 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-17 | — | — | EP | disclosed |
| EP-0214779-A1 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | MRGPRX4 403/4885MAOB 889/4885NR4A2 365/4885 |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | MRGPRX4 403/4885MAOB 889/4885NR4A2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.